StockData
BioNexus Gene Lab Corp logo

BioNexus Gene Lab Corp (BGLC) stock

BGLCNasdaqServices-Medical LaboratoriesFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 14, 2026Score 8/3089% below fair value
$0.77−0.05 (-6.56%)

Close on Nov 17, 2026Market cap $2.25MP/E –Yield –

BioNexus Gene Lab price to sales ratio

The price-to-sales ratio is market cap divided by revenue over the trailing twelve months.

BioNexus Gene Lab's price to sales ratio was 0.7× on Nov 11, 2026, against 0.9× a year earlier. Over the last 4 years it ranged from 0.4× to 448.3×, with a median of 7.9×.

Price to Sales Ratio at the end of each year

PeriodPeriod endValueChange (pts)
2026Nov 11, 20260.7×−0.1
2025Dec 31, 20250.7×−4.7
2024Dec 31, 20245.4×−3.7
2023Dec 29, 20239.1×−135.9
2020Aug 31, 2020145.0×–

More BioNexus Gene Lab figures

See a number that looks wrong?